Transcriptomics

Dataset Information

0

ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models


ABSTRACT: Hepatocellular carcinoma (HCC) currently lacks effective therapies, leaving a critical need for new treatment options. A previous study identified the Anaplastic Lymphoma Kinase (ALK) amplification in HCC patients, raising the question of whether ALK inhibitors could be a viable treatment. Here, we showed that both ALK inhibitors and ALK knockout effectively halted HCC growth in cell cultures. Lorlatinib, a potent ALK inhibitor, suppressed HCC tumor growth and metastasis across various mouse models. Additionally, in an advanced immunocompetent humanized mouse model, when combined with an anti-PD-1 antibody, lorlatinib more potently suppressed HCC tumor growth, surpassing individual drug efficacy. Lorlatinib induced apoptosis and senescence in HCC cells, and the senolytic agent ABT-263 enhanced the efficacy of lorlatinib. Additional studies identified that the apoptosis-inducing effect of lorlatinib was mediated via GGN and NRG4. These findings establish ALK inhibitors as promising HCC treatments, either alone or in combination with immunotherapies or senolytic agents.

ORGANISM(S): Homo sapiens

PROVIDER: GSE178211 | GEO | 2024/04/29

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

| PRJNA737761 | ENA
2022-08-15 | GSE185042 | GEO
2022-12-16 | GSE207324 | GEO
2022-12-16 | GSE207256 | GEO
| S-EPMC3527691 | biostudies-literature
| S-EPMC3871201 | biostudies-literature
| S-EPMC3176271 | biostudies-other
| S-EPMC2921948 | biostudies-literature
2024-04-05 | PXD036716 | Pride
| S-EPMC4728412 | biostudies-literature